Hjem › Non-Hodgkins lymfom › Maryland
Kliniske studier for Non-Hodgkins lymfom i Maryland
21 studier for Non-Hodgkins lymfom søker deltakere på steder i Maryland.
Byer i Maryland
Offisiell studietekst (engelsk)
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- American Oncology Partners of Maryland Pa, Bethesda
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 5. okt. 2026 · NCT05006716Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
RekruttererTidlig fase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 5. okt. 2026 · NCT06398457CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
- National Institutes of Health Clinical Center, Bethesda
RekruttererFase 1/2
Alder 3 til 39 · Alle kjønn · Oppdatert 30. sep. 2026 · NCT05442515A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
- GC2202 Study Site 111, Bethesda
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 30. sep. 2026 · NCT05645107Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
- National Institutes of Health Clinical Center, Bethesda
RekruttererFase 1/2
Alder 18 til 120 · Alle kjønn · Oppdatert 28. sep. 2026 · NCT03223610Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
- National Institutes of Health Clinical Center, Bethesda
RekruttererObservasjonsstudie
Alder 18 til 120 · Alle kjønn · Oppdatert 28. sep. 2026 · NCT02682667Tissue Collection for Studies of Lymph Cancer
- National Institutes of Health Clinical Center, Bethesda
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT01676805Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease
- National Institutes of Health Clinical Center, Bethesda
RekruttererFase 2
Alder 18 til 120 · Alle kjønn · Oppdatert 25. sep. 2026 · NCT05907759Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
- National Institutes of Health Clinical Center, Bethesda
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT01087333Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
- National Institutes of Health Clinical Center, Bethesda
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 16. sep. 2026 · NCT04002947Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- University of Maryland, Baltimore
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 8. sep. 2026 · NCT03666000Toxin Exposure and Immune Dysregulation in Non-Hodgkin Lymphoma
- Walter Reed National Military Medical Center, Bethesda
RekruttererObservasjonsstudie
Alder 4 og eldre · Alle kjønn · Oppdatert 3. sep. 2026 · NCT07652580Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
- National Institutes of Health Clinical Center, Bethesda
RekruttererFase 1
Alder 18 til 120 · Alle kjønn · Oppdatert 25. aug. 2026 · NCT05389423A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- American Oncology Partners of Maryland, PA, Bethesda
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 17. aug. 2026 · NCT05254743Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
- University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 5. aug. 2026 · NCT06116110DALY II USA/ MB-CART2019.1 for DLBCL
- University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 13. jul. 2026 · NCT04792489A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Johns Hopkins, Baltimore
- Nih/Niaid, Bethesda
- Nih/Nhlbi, Bethesda
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 6. jul. 2026 · NCT01351545Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
- The Center for Cancer and Blood Disorders (CCBD), Bethesda
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 24. jun. 2026 · NCT04068597Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- Christiana Care - Union Hospital, Elkton
- og 3 flere
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 17. mar. 2026 · NCT06418204AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- University of Maryland Medical Center - Greenebaum Comprehensive Cancer Center, Baltimore
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 10. des. 2025 · NCT05602363SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Baltimore
- Massive Bio SYNERGY-AI site, Bethesda
- Massive Bio SYNERGY-AI site, Silver Spring
- og 1 flere
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 28. okt. 2025 · NCT03452774Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.